Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors
Sponsor: Abbott
A observational or N/A phase clinical study on Breast Carcinoma and Carcinoma of Unknown Primary, this trial is ongoing. The trial is conducted by Abbott and has accumulated 42 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Study Description(click to expand)PRIMARY OBJECTIVES: I. To determine the pharmacokinetics and pharmacodynamics of ABT-888 (veliparib) in patients with varying degrees of renal or hepatic dysfunction. II. To determine the maximum tolerated dose (MTD) of ABT-888 in combination with carboplatin and paclitaxel for patients with varying degrees of liver or kidney dysfunction. III. To provide dosing recommendations for ABT-888 in combination with carboplatin and paclitaxel based on degree of hepatic and renal impairment. SECONDARY OBJECTIVES: I. To define the dose-limiting toxicity (DLT) and other toxicities associated with the use of this combination in patients with varying degrees of renal or hepatic dysfunction. II. To evaluate the pharmacokinetic parameters of ABT-888, carboplatin, and paclitaxel when administered as a combination in patients with varying degrees of renal or hepatic dysfunction. III. To evaluate the pharmacodynamic measurement of poly-ADP-ribosylated (PAR) and platinum adducts in tumor cells associated with the use of this combination in patients with varying degrees of renal or hepatic dysfunction. OUTLINE: This is a dose-escalation study of veliparib. Patients receive veliparib\* orally (PO) twice daily (BID) on days 1-7 and paclitaxel intravenously (IV) over 3 hours and carboplatin IV over 30 minutes on day 3. Treatment repeats every 21 days for 6 courses in...
PRIMARY OBJECTIVES:
I. To determine the pharmacokinetics and pharmacodynamics of ABT-888 (veliparib) in patients with varying degrees of renal or hepatic dysfunction.
II. To determine the maximum tolerated dose (MTD) of ABT-888 in combination with carboplatin and paclitaxel for patients with varying degrees of liver or kidney dysfunction.
III. To provide dosing recommendations for ABT-888 in combination with carboplatin and paclitaxel based on degree of hepatic and renal impairment.
SECONDARY OBJECTIVES:
I. To define the dose-limiting toxicity (DLT) and other toxicities associated with the use of this combination in patients with varying degrees of renal or hepatic dysfunction.
II. To evaluate the pharmacokinetic parameters of ABT-888, carboplatin, and paclitaxel when administered as a combination in patients with varying degrees of renal or hepatic dysfunction.
III. To evaluate the pharmacodynamic measurement of poly-ADP-ribosylated (PAR) and platinum adducts in tumor cells associated with the use of this combination in patients with varying degrees of renal or hepatic dysfunction.
OUTLINE: This is a dose-escalation study of veliparib.
Patients receive veliparib\* orally (PO) twice daily (BID) on days 1-7 and paclitaxel intravenously (IV) over 3 hours and carboplatin IV over 30 minutes on day 3. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
NOTE: \* All patients receive a single dose of veliparib PO on day -6 before course 1 (except patients with very severe renal dysfunction who receive veliparib on day -5 or -6 to coincide with a dialysis day).
After completion of study treatment, patients are followed up for 4 weeks.
Status Flow
Change History
42 versions recorded-
Apr 13, 2026 — Present [daily]
Active Not Recruiting
Phase: PHASE1 → None
-
Mar 2026 — Present [monthly]
Active Not Recruiting PHASE1
-
Jan 2026 — Present [monthly]
Active Not Recruiting PHASE1
-
Oct 2025 — Mar 2026 [monthly]
Active Not Recruiting PHASE1
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE1
▶ Show 37 earlier versions
-
Apr 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE1
-
Nov 2024 — Apr 2025 [monthly]
Active Not Recruiting PHASE1
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE1
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
-
Apr 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE1
-
Mar 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE1
-
Dec 2023 — Mar 2024 [monthly]
Active Not Recruiting PHASE1
-
Nov 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE1
-
Oct 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE1
-
Feb 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE1
-
Sep 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE1
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE1
-
May 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE1
-
Jan 2022 — May 2022 [monthly]
Active Not Recruiting PHASE1
-
Sep 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE1
-
Apr 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE1
-
Jun 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
-
May 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE1
-
Apr 2020 — May 2020 [monthly]
Active Not Recruiting PHASE1
-
Mar 2020 — Apr 2020 [monthly]
Active Not Recruiting PHASE1
-
Jan 2020 — Mar 2020 [monthly]
Active Not Recruiting PHASE1
-
Dec 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE1
-
Nov 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE1
-
Sep 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE1
-
Jul 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE1
-
Jun 2019 — Jul 2019 [monthly]
Active Not Recruiting PHASE1
Status: Suspended → Active Not Recruiting
-
Mar 2019 — Jun 2019 [monthly]
Suspended PHASE1
-
Jan 2019 — Mar 2019 [monthly]
Suspended PHASE1
-
Aug 2018 — Jan 2019 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE1
-
Jun 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Feb 2017 — Jun 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Jun 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
This phase I trial studies the side effects and the best dose of veliparib when given together with paclitaxel and carboplatin in treating patients with solid tumors that are metastatic or cannot be removed by surgery and liver or kidney dysfunction. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib together with paclitaxel and carboplatin may kill more tumor cells.
Contact Information
- Abbott
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .